MALDI imaging on tissue microarrays identifies molecular features associated with renal cell cancer phenotype

Anticancer Research

Volumn 34, Issue 5, 2014, Pages 2255-2262

  Steurer, Stefan ^a   Seddiqi, Ahmad Shoaib ^a   Singer, Julius Magnus ^a   Bahar, Ahmad Soliaman ^a   Eichelberg, Christian ^a   Rink, Michael ^a   Dahlem, Roland ^a   Huland, Hartwig ^a   Sauter, Guido ^a   Simon, Ronald ^a   Minner, Sarah ^a   Burandt, Eike ^a   Stahl, Phillip R ^a   Schlomm, Thorsten ^a   Wurlitzer, Marcus ^a   Schlu, Hartmut ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Biomarker; MALDI mass spectrometry imaging; MALDI MSI; Renal cell cancer; Tissue microarray

Indexed keywords

EOSIN; HEMATOXYLIN; BIOLOGICAL MARKER;

ADULT; AGED; ARTICLE; CANCER CELL; CANCER STAGING; CLEAR CELL CARCINOMA; CLINICAL FEATURE; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; KIDNEY CARCINOMA; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; TISSUE MICROARRAY; CANCER GRADING; KIDNEY TUMOR; MALDI MASS SPECTROMETRY IMAGING; MALDI-MSI; MASS SPECTROMETRY; METABOLISM; METHODOLOGY; MIDDLE AGED; MORTALITY; PATHOLOGY; PHENOTYPE; RENAL CELL CANCER;

BIOMARKER; MALDI MASS SPECTROMETRY IMAGING; MALDI-MSI; RENAL CELL CANCER; TISSUE MICROARRAY;

AGED; CARCINOMA, RENAL CELL; FEMALE; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; PHENOTYPE; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TISSUE ARRAY ANALYSIS;

EID: 84902994401     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Jemal A, Siegel R, Xu J and Ward E: Cancer statistics, 2010. CA Cancer J Clin 60: 277-300, 2010.
2. Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P, Leighton S, Torhorst J, Mihatsch MJ, Sauter G and Kallioniemi OP: Tissue microarrays for high-throughput molecular profiling of tumor specimens. 4: 844-847, 1998.
3. Cornett DS, Reyzer ML, Chaurand P and Caprioli RM: MALDI imaging mass spectrometry: molecular snapshots of biochemical systems. 4: 828-833, 2007.
4. Steurer S, Borkowski C, Odinga S, Buchholz M, Koop C, Huland H, Becker M, Witt M, Trede D, Omidi M, Kraus O, Bahar AS, Seddiqi AS, Singer JM, Kwiatkowski M, Trusch M, Simon R, Wurlitzer M, Minner S, Schlomm T, Sauter G and Schluter H: MALDI mass spectrometric imaging based identification of clinically relevant signals in prostate cancer using large-scale tissue microarrays. Int J Cancer 133: 920-928, 2013.
5. Lam JS, Klatte T, Kim HL, Patard JJ, Breda A, Zisman A, Pantuck AJ and Figlin RA: Prognostic factors and selection for clinical studies of patients with kidney cancer. Crit Rev Oncol Hematol 65: 235-262, 2008.
6. Weiss RH, Borowsky AD, Seligson D, Lin P Y, Dillard-Telm L, Belldegrun AS, Figlin RA and Pantuck AD: p21 is a prognostic marker for renal cell carcinoma: implications for novel therapeutic approaches. J Urol 177: 63-68; discussion 68-69, 2007.
7. Shvarts O, Seligson D, Lam J, Shi T, Horvath S, Figlin R, Belldegrun A and Pantuck AJ: p53 is an independent predictor of tumor recurrence and progression after nephrectomy in patients with localized renal cell carcinoma. J Urol 173: 725-728, 2005.
8. Kim HL, Seligson D, Liu X, Janzen N, Bui MH, Yu H, Shi T, Figlin RA, Horvath S and Belldegrun AS: Using protein expressions to predict survival in clear cell renal carcinoma. Clin Cancer Res 10: 5464-5471, 2004.
9. Sandlund J, Oosterwijk E, Grankvist K, Oosterwijk-Wakka J, Ljungberg B and Rasmuson T: Prognostic impact of carbonic anhydrase IX expression in human renal cell carcinoma. BJU Int 100: 556-560, 2007.
10. Lidgren A, Hedberg Y, Grankvist K, Rasmuson T, Vasko J and Ljungberg B: The expression of hypoxia-inducible factor 1alpha is a favorable independent prognostic factor in renal cell carcinoma. Clin Cancer Res 11: 1129-1135, 2005.
11. Campbell L, Nuttall R, Griffiths D and Gumbleton M: Activated extracellular signal-regulated kinase is an independent prognostic factor in clinically confined renal cell carcinoma. Cancer 115: 3457-3467, 2009.
12. Campbell L, Gumbleton M and Griffiths DF: Caveolin-1 overexpression predicts poor disease-free survival of patients with clinically confined renal cell carcinoma. Br J Cancer 89: 1909-1913, 2003.
13. Campbell L, Jasani B, Edwards K, Gumbleton M and Griffiths DF: Combined expression of caveolin-1 and an activated AKT/mTOR pathway predicts reduced disease-free survival in clinically confined renal cell carcinoma. Br J Cancer 98: 931-940, 2008.
14. Junker H, Venz S, Zimmermann U, Thiele A, Scharf C and Walther R: Stage-related alterations in renal cell carcinoma-comprehensive quantitative analysis by 2D-DIGE and protein network analysis. PLoS One 6: e21867, 2011.
15. Oppenheimer SR, Mi D, Sanders ME and Caprioli RM: Molecular analysis of tumor margins by MALDI mass spectrometry in renal carcinoma. J Proteome Res 9: 2182-2190, 2010.
16. Chinello C, Gianazza E, Zoppis I, Mainini V, Galbusera C, Picozzi S, Rocco F, Galasso G, Bosari S, Ferrero S, Perego R, Raimondo F, Bianchi C, Pitto M, Signorini S, Brambilla P, Mocarelli P, Galli Kienle M and Magni F: Serum biomarkers of renal cell carcinoma assessed using a protein profiling approach based on ClinProt technique. Urology 75: 842-847, 2010.
17. Yang J, Li A, Yang Y and Li X: Identification of cyclophilin A as a potential prognostic factor for clear-cell renal cell carcinoma by comparative proteomic analysis. Cancer Biol Ther 11: 535-546, 2011.
18. Gancberg D, Jarvinen T, di Leo A, Rouas G, Cardoso F, Paesmans M, Verhest A, Piccart MJ, Isola J and Larsimont D: Evaluation of HER-2/NEU protein expression in breast cancer by immunohistochemistry: an interlaboratory study assessing the reproducibility of HER-2/NEU testing 74: 113-120, 2002.
19. Le Faouder J, Laouirem S, Chapelle M, Albuquerque M, Belghiti J, Degos F, Paradis V, Camadro JM and Bedossa P: Imaging mass spectrometry provides fingerprints for distinguishing hepatocellular carcinoma from cirrhosis. J Proteome Res 10: 3755-3765, 2011.
20. Kriegsmann M, Seeley EH, Schwarting A, Kriegsmann J, Otto M, Thabe H, Dierkes B, Biehl C, Sack U, Wellmann A, Kahaly GJ, Schwamborn K and Caprioli RM: MALDI MS imaging as a powerful tool for investigating synovial tissue. Scand J Rheumatol 41: 305-309, 2012.
21. Mark L, Maasz G and Pirger Z: High resolution spatial distribution of neuropeptides by MALDI imaging mass spectrometry in the terrestrial snail, Helix pomatia. Acta Biol Hung 63(Suppl 2): 113-122, 2012.
22. Acquadro E, Cabella C, Ghiani S, Miragoli L, Bucci EM and Corpillo D: Matrix-Assisted laser desorption ionization imaging mass spectrometry detection of a magnetic resonance imaging contrast agent in mouse liver. Anal Chem 81: 2779-2784, 2009.
23. Shanta SR, Choi CS, Lee JH, Shin CY, Kim YJ, Kim KH and Kim KP: Global changes in phospholipids identified by MALDI MS in rats with focal cerebral ischemia. J Lipid Res 53: 1823-1831, 2012.
24. Lazova R, Seeley EH, Keenan M, Gueorguieva R and Caprioli RM: Imaging mass spectrometry-A new and promising method to differentiate Spitz nevi from Spitzoid malignant melanomas. Am J Dermatopathol 34: 82-90, 2012.
25. Gustafsson JO, Oehler MK, McColl SR and Hoffmann P: Citric acid antigen retrieval (CAAR) for tryptic peptide imaging directly on archived formalin-fixed paraffin-embedded tissue. J Proteome Res 9: 4315-4328, 2010.
26. Djidja MC, Claude E, Snel MF, Scriven P, Francese S, Carolan V and Clench MR: MALDI-ion mobility separation-mass spectrometry imaging of glucose-regulated protein 78 kDa (Grp78) in human formalin-fixed, paraffin-embedded pancreatic adenocarcinoma tissue sections. J Proteome Res 8: 4876-4884, 2009.